Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Fig. 5

Preexisting immunity to HLA-A2 and HLA-A24-restricted CTL epitopes affects progression free survival. HLA-A2+ patients having high preexisting immunity to E75 showed a trend for shorter mPFS compared to them with low one (a). Patients with high Rmax/R0 had a trend for decreased mPFS, compared to patients with low Rmax/R0 (b). No statistically significant differences were observed among patients having high or low preexisting immunity to PSA146 and high or low Rmax/R0 (c, d). HLA-A24+ patients having high preexisting immunity to PSA153 showed statistically significant longer mPFS compared to patients with low (e). No statistically significant differences were observed among patients having high or low Rmax/R0 (f)

Back to article page